Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: MK 341; NU3450; Rizaben; SB 252218

Latest Information Update: 12 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; Nuon Therapeutics
  • Class Anthranilic acids; Antiallergics; Antiasthmatics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Collagen inhibitors; Immunomodulators; Mast cell stabilisers; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-myc modulators; SLC2A9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Asthma; Atopic dermatitis; Hypertrophic scars; Keloids
  • Discontinued Cancer metastases; Coronary artery restenosis; Hyperuricaemia; Multiple sclerosis; Rheumatoid arthritis; Vascular restenosis

Most Recent Events

  • 31 Dec 2010 Nuon Therapeutics completes a phase II trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Germany, Mexico, Serbia & United Kingdom
  • 28 May 2010 Tranilast is still in phase II trials for Rheumatoid arthritis worldwide except Japan and South Korea (http://www.kissei.co.jp/e_contents/relation/pipeline.html)
  • 24 Jul 2007 Kissei Pharmaceutical and Nuon Therapeutics enter into a licensing, supply and collaboration agreement for tranilast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top